Related Experiment Videos
Radiation therapy for primary orbital lymphoma
C K Chao1, H S Lin, V R Devineni
1Division of Radiation Oncology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110.
International Journal of Radiation Oncology, Biology, Physics
|February 15, 1995
Summary
Thirty Gy of radiation effectively controls primary orbital lymphoma, with minimal systemic spread when staging is thorough. This dose shows acceptable side effects, including cataracts and lacrimal dysfunction, in patients with low-grade or certain intermediate-grade lymphomas.
Area of Science:
- Ophthalmology
- Radiation Oncology
- Hematology
Background:
- Primary orbital lymphoma is a rare malignancy.
- Accurate staging and treatment are crucial for disease control and minimizing complications.
Purpose of the Study:
- To analyze the impact of tumor size, grade, staging, and radiation dose on outcomes for primary orbital lymphoma.
- To evaluate disease control, radiation-related complications, and systemic progression.
Main Methods:
- Retrospective analysis of 20 Stage I primary orbital lymphoma patients treated with radiation therapy.
- Staging included physical examination, imaging (CT scans), and bone marrow biopsy.
- Radiation doses ranged from 20 to 43.2 Gy, with 13 patients receiving 30 Gy.
Main Results:
- All 20 patients achieved local control.
- Disease-free survival was 100% at 2 years and 90% at 5 years.
- Complications included cataracts (7 patients) and lacrimal dysfunction (3 patients); no retinopathy or corneal ulceration occurred.
Conclusions:
- A dose of 30 Gy in 15 fractions is sufficient for local control of low-grade and certain intermediate-grade orbital lymphomas.
- Adequate staging and local control minimize the risk of systemic dissemination.
- Treatment offers acceptable morbidity with good long-term disease control.